Under future technical and commercial agreements, Angel will utilize its GMP facility at Cramlington to expedite and optimize the expression systems provided by TransGenRx.
TransGenRx chief scientific officer Richard Cooper said that they require Angel’s expertise to fast track the scale up of their pipeline of products to GMP.
"Angel has a reputation for delivering challenging advanced biologics. The team at Angel is committed to this end and has the capabilities we require," Cooper added.